Shots:
- Novartis has reported the topline P-III (Lp(a)HORIZON) trial data assessing pelacarsen vs PBO on the incidence of 4-point major adverse CV events (MACE) in 8,323 pts with elevated Lp(a) & established CVD
- Pelacarsen did not meet its 1EP of reducing major CV events, despite lowering Lp(a) levels in pts receiving guideline-directed lipid-lowering & antihypertensive therapies; data to be presented at an upcoming conference
- Pelacarsen is an ASO designed to inhibit Lp(a) production, with Novartis holding global development, manufacturing & commercialization rights through its collaboration with Ionis Pharmaceuticals
Ref: Globenewswire | Image: Novartis | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
